Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) ...
CytomX Therapeutics Inc (CTMX) reports encouraging results from its Varseta-M study, with plans for a pivotal trial and expansion into new tumor types.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results